We are live on ! Find out more
ENZ

Enzo Biochem, Inc.

Delisted

ENZ was delisted on the 17th of April, 2025.

109 hedge funds and large institutions have $237M invested in Enzo Biochem, Inc. in 2017 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 37 increasing their positions, 35 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

56% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 9

26% more capital invested

Capital invested by funds: $188M → $237M (+$48.7M)

6% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 35

0% more funds holding

Funds holding: 109109 (0)

Holders
109
Holders Change
Holders Change %
0%
% of All Funds
2.71%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
14
Increased
37
Reduced
35
Closed
9
Calls
$357K
Puts
Net Calls
+$357K
Net Calls Change
-$10K
Name Holding Trade Value Shares
Change
Change in
Stake
PPA
51
Parametric Portfolio Associates
Washington
$310K -$100K -14,262 -28%
RJT
52
Raymond James Trust
Florida
$293K
Connor, Clark & Lunn Investment Management (CC&L)
53
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$274K +$12K +1,700 +5%
Manulife (Manufacturers Life Insurance)
54
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$271K +$28.1K +3,988 +14%
MLICM
55
Metropolitan Life Insurance Company (MetLife)
New York
$266K -$2.49K -353 -1%
SIM
56
Spark Investment Management
New York
$242K -$486K -69,000 -70%
PCM
57
Prelude Capital Management
New York
$241K +$61.3K +8,700 +43%
Bank of America
58
Bank of America
North Carolina
$239K +$121K +17,118 +149%
KBC Group
59
KBC Group
Belgium
$237K
MWNA
60
Marshall Wace North America
New York
$235K +$207K +29,432 New
Millennium Management
61
Millennium Management
New York
$224K -$527K -74,829 -74%
Balyasny Asset Management
62
Balyasny Asset Management
Illinois
$223K +$188K +26,628 New
JP Morgan Chase
63
JP Morgan Chase
New York
$220K +$185K +26,241 New
AIG
64
American International Group
New York
$204K +$11.3K +1,610 +7%
Neuberger Berman Group
65
Neuberger Berman Group
New York
$202K -$627 -89 -0.4%
GC
66
Globeflex Capital
California
$188K -$1.42M -201,511 -90%
VOYA Investment Management
67
VOYA Investment Management
Georgia
$187K
Barclays
68
Barclays
United Kingdom
$181K -$405K -57,454 -73%
Allianz Asset Management
69
Allianz Asset Management
Germany
$164K +$138K +19,628 New
State Board of Administration of Florida Retirement System
70
State Board of Administration of Florida Retirement System
Florida
$163K
Bank of Montreal
71
Bank of Montreal
Ontario, Canada
$150K
Prudential Financial
72
Prudential Financial
New Jersey
$149K +$126K +17,830 New
ZIM
73
Zacks Investment Management
Illinois
$147K -$269K -38,158 -68%
VKH
74
Virtu KCG Holdings
New York
$141K +$118K +16,800 New
TC
75
TFS Capital
Pennsylvania
$127K -$14K -1,985 -12%

ENZ Hedge Fund Activity: Q1 2017 in Review

109 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q1 2017, worth a combined $237M — up 26% from $188M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new ENZ positions and 9 closed out — a net gain of 5 holders — while 37 added to existing stakes and 35 trimmed.

The largest buyer was BlackRock, adding an estimated $22.4M. The largest seller was Globeflex Capital, cutting an estimated $1.42M.

  • 109 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q1 2017, unchanged from Q4 2016.
  • Funds reported $237M of Enzo Biochem, Inc. stock for Q1 2017, up 26% quarter-over-quarter.
  • 14 funds opened new Enzo Biochem, Inc. positions in Q1 2017 and 9 closed out, a net change of +5 holders.
  • The largest Enzo Biochem, Inc. buyer in Q1 2017 was BlackRock, an estimated $22.4M added.
  • The largest Enzo Biochem, Inc. seller in Q1 2017 was Globeflex Capital, an estimated $1.42M sold.

Based on aggregated 13F filings for Q1 2017.